Yescarta - Drug Monograph

Introduction

Yescarta (axicabtagene ciloleucel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved for the treatment of certain relapsed or refractory B-cell malignancies. It represents a paradigm shift in hemato-oncology, offering a potentially curative single-infusion option for patients with aggressive lymphomas who previously had limited effective therapies. Its clinical relevance is grounded in durable complete remission rates observed in heavily pretreated populations and its incorporation into current major oncology guidelines.

Drug Class and Overview

• Class: Autologous cellular immunotherapy; CD19-directed CAR-T cell product.
• Related agents: Tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), lisocabtagene maraleucel (Breyanzi).
• Distinguishing features:
• Constructed using a retroviral vector encoding an anti-CD19 single-chain variable fragment (scFv) linked to a CD28 costimulatory domain and a CD3ζ T-cell activation domain.
• Manufactured as a patient-specific, single-dose, single-vial product with a CD28 (rather than 4-1BB) costimulatory domain, which contributes to rapid in vivo expansion and a characteristic early-onset adverse-event profile.
• Available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.

Mechanism of Action

Yescarta is generated by collecting autologous peripheral blood T cells via leukapheresis, transducing them ex vivo with a replication-incompetent gamma-retroviral vector encoding an anti-CD19 CAR. After lymphodepleting chemotherapy, the engineered T cells are reinfused into the patient. The CAR recognizes the CD19 antigen on the surface of normal and malignant B cells. Engagement triggers T-cell activation, proliferation, cytokine release, and cytolysis of CD19-positive target cells. B-cell aplasia and resultant hypogammaglobulinemia are expected pharmacodynamic effects reflecting on-target activity.

Indications

• Adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
• Adult patients with LBCL that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (based on the ZUMA-7 trial).
• Adult patients with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of systemic therapy.

Dosage and Administration

• Dose: Target of 2 × 10⁶ CAR-positive viable T cells per kg body weight, with a maximum of 2 × 10⁸ CAR-positive viable T cells (per FDA prescribing information). Dosing is weight-based up to a flat cap; treatment consists of a single intravenous infusion.
• Lymphodepleting chemotherapy: Fludarabine 30 mg/m² and cyclophosphamide 500 mg/m² IV on each of the 3 days (Days −5, −4, −3) preceding Yescarta infusion. Adjust or omit in patients with significant renal or hepatic impairment based on standard chemotherapy practice.
• Bridging therapy: Limited use of corticosteroids for symptom control before infusion is permissible, but systemic corticosteroids should be avoided in the days immediately preceding and following infusion whenever possible due to potential interference with T-cell activity.
• Premedication: Acetaminophen and diphenhydramine (or equivalent H1 antagonist) approximately 30–60 minutes before infusion to reduce infusion reactions. Avoid prophylactic systemic corticosteroids.
• Special populations:
• Pediatric: Not approved for use in pediatric patients.
• Geriatric: No dose adjustment required; effectiveness and safety have been documented in older adults, though careful evaluation of comorbidities is warranted.
• Renal/hepatic impairment: No formal dose adjustments established; consider the impact of organ function on the fludarabine/cyclophosphamide conditioning regimen.
• Pregnancy/lactation: Contraindicated in pregnancy based on mechanism (B-cell aplasia and lymphodepletion risk to the fetus); contraception is recommended during and for an extended period after treatment.

Pharmacokinetics

Yescarta is composed of living cells, so traditional absorption/distribution/metabolism parameters do not apply.

• Expansion: CAR-T cells typically undergo rapid in vivo expansion, with peak peripheral blood levels approximately 7–14 days post-infusion.
• Persistence: CAR-T cells may remain detectable in peripheral blood for months to years, with B-cell aplasia sustained during persistence.
• Factors influencing exposure: Manufacturing yield, tumor burden, and the degree of lymphodepletion can influence expansion and persistence.
• Elimination: Cell-mediated clearance and immune-mediated mechanisms; not metabolized by CYP enzymes.

Contraindications

• None listed as absolute in the FDA label, but treatment should not be pursued in patients with:
• Active uncontrolled infection.
• Severe, rapidly progressive disease or significant organ dysfunction that would preclude safe administration of lymphodepleting chemotherapy.
• Pregnancy (relative, based on mechanism and conditioning regimen).

Warnings and Precautions

• Boxed warnings:
• Cytokine release syndrome (CRS): Graded by ASTCT criteria; may be life-threatening or fatal. Management includes tocilizumab and corticosteroids as indicated.
• Neurologic toxicities / ICANS: Encephalopathy, tremor, aphasia, seizures, and cerebral edema have been reported; may occur concurrently with, after resolution of, or independently of CRS.
• Other major precautions:
• Prolonged cytopenias: Anemia, neutropenia, and thrombocytopenia persisting weeks beyond infusion.
• Hypogammaglobulinemia and B-cell aplasia: Monitor immunoglobulin levels and consider IVIG replacement.
• Infections and febrile neutropenia: Reactivation of HBV, severe opportunistic infections, and prolonged neutropenia-related infections may occur.
• Secondary malignancies: T-cell malignancies, including CAR-positive cases, have been reported with CAR-T therapies; lifelong monitoring is recommended.
• Hypersensitivity reactions: During or shortly after infusion.
• REMS program: Because of the risk of CRS and neurologic toxicities, Yescarta is available only through certified prescribers and treatment centers participating in the Yescarta REMS.

Drug Interactions

• CYP-related interactions: Not applicable; cell-based therapy not metabolized by cytochrome enzymes.
• Corticosteroids and immunosuppressants: Systemic corticosteroids (especially >24 hours around infusion) may impair CAR-T expansion and persistence; use at the lowest effective dose and only for management of severe CRS or ICANS.
• Live vaccines: Avoid during the period of B-cell aplasia and until immune reconstitution.
• Anti-IL-6 therapy: Tocilizumab is used to manage CRS; it does not appear to compromise Yescarta efficacy.
• Supportive medications: Granulocyte colony-stimulating factors may be used for neutropenia, but should be given only after CRS has resolved, per label guidance.

Adverse Effects

• Very common (≥20%): Cytopenias (anemia, neutropenia, thrombocytopenia), fever, fatigue, hypotension, cytokine release syndrome, ICANS/neurologic symptoms, hypogammaglobulinemia, infections, nausea, diarrhea, headache, and decreased appetite.
• Common (10–20%): Tachycardia, hypoxia, chills, edema, abdominal pain, constipation, dyspnea, insomnia, arthralgia/myalgia, and tremor.
• Serious/rare but important: Severe or life-threatening CRS, severe neurotoxicity including cerebral edema, prolonged pancytopenia, opportunistic infections, secondary T-cell malignancies, tumor lysis syndrome, and cardiac arrhythmias.

Monitoring Parameters

• Pre-infusion: CBC with differential, comprehensive metabolic panel, LDH, ferritin, CRP, coagulation profile, immunoglobulin levels, viral serologies (HBV, HCV, HIV, CMV as indicated), pregnancy test if applicable, and disease restaging with PET-CT.
• During and immediately after infusion: Continuous vital signs and frequent neurologic checks (at least every 8 hours for the first 7 days) for early identification of CRS and ICANS; cardiac monitoring in higher-risk patients.
• Daily labs for at least the first 7–14 days: CBC, CMP, CRP, and ferritin to assess CRS trajectory and organ function.
• Long-term follow-up: Periodic CBC, quantitative immunoglobulins, and immune reconstitution studies; lifelong surveillance for secondary malignancies (especially T-cell malignancies); and B-cell recovery assessment.

Patient Education

• Explain the multi-step process: leukapheresis, manufacturing, lymphodepleting chemotherapy, and the single CAR-T infusion.
• Stay within 2 hours of the treatment center for at least 4 weeks after infusion.
• Report immediately: fever ≥38°C/100.4°F, chills, low blood pressure, shortness of breath, confusion, difficulty speaking, tremor, or seizures.
• Avoid driving, operating heavy machinery, and engaging in activities requiring full alertness for at least 8 weeks after infusion due to neurologic risk.
• Use effective contraception during and after therapy as advised; do not donate blood, organs, tissues, or cells.
• Avoid live vaccines until immune reconstitution.
• Maintain follow-up visits for bloodwork, imaging, and long-term monitoring of immune function and relapse.

Clinical Pearls

1. Yescarta's CD28 costimulatory domain confers rapid in vivo expansion, producing an earlier and often more pronounced CRS and ICANS profile compared with 4-1BB–based products; early recognition and prompt tocilizumab ± corticosteroid therapy are essential.
2. Always rule out active infection and confirm adequate organ function before proceeding with leukapheresis and lymphodepletion; bridging therapy may be required but should be carefully selected to preserve CAR-T fitness.
3. Tocilizumab, not corticosteroids, is first-line for moderate to severe CRS; corticosteroids are reserved for severe or refractory CRS and ICANS.
4. B-cell aplasia is both an expected on-target effect and a useful surrogate for functional CAR-T persistence; persistent aplasia correlates with ongoing disease control in many patients.
5. Patients should be enrolled in long-term registries; secondary T-cell malignancies, while rare, have prompted FDA class labeling and require lifelong monitoring.
6. The REMS requirement is non-negotiable—Yescarta may only be administered at certified centers, with documented training in CRS/ICANS management algorithms.

References

1. Kite Pharma, Inc. Yescarta (axicabtagene ciloleucel) Prescribing Information. U.S. Food and Drug Administration; rev. 2024.
2. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7). New England Journal of Medicine. 2022;386:640-654.
3. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (ZUMA-1). New England Journal of Medicine. 2017;377:2531-2544.
4. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5). New England Journal of Medicine. 2021;384:2007-2019.
5. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation. 2019;25:625-638.
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Current version.
7. U.S. Food and Drug Administration. Yescarta Risk Evaluation and Mitigation Strategy (REMS). FDA-approved REMS program documentation.
8. European Medicines Agency. Yescarta (axicabtagene ciloleucel) Summary of Product Characteristics. EMA, current revision.
9. Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma (BELINDA trial). New England Journal of Medicine. 2021;386:629-639.
10. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma (TRANSCEND NHL 001). Lancet Oncology. 2020;21:1287-1299.
11. Sharma P, Kasner MT, Budde LE. CAR-T-Cell Therapy in B-Cell Lymphomas: Clinical Updates and Practice Considerations. ASCO Educational Book; current edition.
12. Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023. Chapter on targeted biologics and cellular immunotherapies.